Handelsavisen
prelaunch
Companies Healthcare 300453.SZ
30
300453.SZ Shenzhen Stock Exchange Medical Equipment, Supplies & Distribution

Jiangxi Sanxin Medtec Co Ltd

¥9,50
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
5,0B CNY
P/E
EV / Rev
Div yield
2,98 %
Op margin
18,5 %
ROE
17,2 %
Net margin
15,2 %
Debt / equity
0,18
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Jiangxi Sanxin Medtec Co Ltd is a medical equipment and supplies manufacturer and distributor in China, generating revenue primarily through the sale of medical devices and related healthcare products.

Business. Jiangxi Sanxin Medtec Co Ltd (300453.SZ) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the development and sale of medical devices and related consumables. Headquartered in China, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
17,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300453.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300453.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Jiangxi Sanxin Medtec Co Ltd (300453.SZ) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the development and sale of medical devices and related consumables. Headquartered in China, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Jiangxi Sanxin Medtec maintains a price-to-book ratio of 3.75 and a price-to-tangible-book ratio of 3.75, indicating a premium valuation relative to its equity base. The company's liquidity position is characterized as medium, with a current ratio of 1.43, suggesting moderate short-term solvency. However, the firm's free cash flow is negative at -5,493,520 CNY, and capital expenditures are substantial at -217,537,090 CNY, indicating ongoing investment in operations.

    Profitability metrics show a return on equity of 17.17% and a return on assets of 10.23%, both exceeding the typical thresholds for the medical equipment industry. The company's gross profit of 528,388,010 CNY and operating income of 277,749,000 CNY reflect strong operational efficiency. The debt-to-equity ratio of 0.18 suggests a conservative capital structure with limited leverage.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which may expose it to regional market risks. The firm's revenue of 1,500,438,420 CNY is derived primarily from the sale of medical equipment and supplies, with no material diversification across product lines.

    Looking ahead, the company is projected to grow revenue from 1,500,438,420 CNY to 1,898,000,000 CNY, a 26.5% increase, driven by expansion in its core medical equipment segment. Analysts expect earnings per share to rise from 0.51 CNY to 0.61 CNY, a 19.6% increase, reflecting improved operational performance.

    The company faces a medium liquidity risk due to a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant dilution potential in the near term. The firm's capital expenditures and negative free cash flow suggest a focus on growth through reinvestment rather than shareholder returns.

    Recent filings and transcripts indicate the company is expanding its production capacity to meet growing demand in the domestic healthcare market. The firm has also emphasized cost control measures to maintain profitability amid rising input costs.

    Key takeaways
    • Jiangxi Sanxin Medtec is a high-return medical equipment manufacturer with a conservative capital structure.
    • The company's valuation multiples suggest a premium pricing relative to its equity base.
    • Revenue growth is expected to accelerate in the next fiscal year, driven by expansion in the domestic market.
    • The firm's liquidity position is moderate, with a current ratio of 1.43 and negative free cash flow.
    • The company's business is concentrated in a single segment, which may increase exposure to market-specific risks.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥9,50
    Market cap
    ¥4.96B
    Enterprise value
    ¥5.20B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    13.3x
    P / B
    3.8x
    P / Tangible book
    3.8x
    Tangible book
    ¥1.32B
    Net cash
    -¥237.7M
    Current ratio
    1.4
    Debt / equity
    0.2
    ROA
    10.2%
    ROE
    17.2%
    Cash conversion
    171.0%
    CapEx / revenue
    -14.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,61
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-21 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,61
    Revenueno estimateno estimate1,9B CNY
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data
    EPS surprise
    −16,1 %
    reported vs consensus · miss
    Revenue surprise
    −13,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin18,5 %Above P75
    Net Margin15,2 %Above P75
    ROE17,2 %Best in class
    Capex / Rev-14,5 %Bottom quartile
    D/E0,18Above median
    Cash Conv1,71Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Jiangxi Sanxin Medtec Co Ltd Market data — financials · 2026-05-26
    • Jiangxi Sanxin Medtec Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Leadership

    • Zhiping MaoPresident, Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300453.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage